Merck & Company Inc (MRK)vsRani Therapeutics Holdings Inc (RANI)
MRK
Merck & Company Inc
$130.21
+0.32%
HEALTHCARE · Cap: $307.25B
RANI
Rani Therapeutics Holdings Inc
$0.82
-2.80%
HEALTHCARE · Cap: $92.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2075255% more annual revenue ($65.77B vs $3.17M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
RANI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.21
$48.98 premium
Margin of Safety
+76.2%
Fair Value
$5.25
Current Price
$0.82
$4.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.80 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). RANI offers better value entry with a 76.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the oral administration of biologic therapeutics. This groundbreaking approach not only enhances patient adherence but also aligns with the growing preference for non-invasive treatment options. With a robust and diversified pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned for significant growth. The company’s commitment to cutting-edge research and development, along with key partnerships, further underscores its potential to make impactful advancements in the pharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?